<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02376972</url>
  </required_header>
  <id_info>
    <org_study_id>RFX-VAG/003/2012</org_study_id>
    <nct_id>NCT02376972</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Rifaximin Vaginal Tablets in Bacterial Vaginosis</brief_title>
  <acronym>VARIANT</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Rifaximin Vaginal Tablets in the Treatment of Bacterial Vaginosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alfasigma S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Alfasigma S.p.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      THE STUDY HAS BEEN DESIGNED TO COMPARE THE EFFICACY OF TWO DOSES (25 MG AND 100 MG) OF
      RIFAXIMIN VAGINAL TABLETS VERSUS PLACEBO IN SUBJECTS WITH BACTERIAL VAGINOSIS
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      THIS IS A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY PLANNING TO ENROL 626
      SUBJECTS AFFECTED BY BACTERIAL VAGINOSIS.

      PRIMARY ENDPOINT:

      TO COMPARE THE EFFICACY OF TWO DOSES (25 MG AND 100 MG) OF RIFAXIMIN VAGINAL TABLETS VERSUS
      PLACEBO IN SUBJECTS WITH BACTERIAL VAGINOSIS

      SECONDARY ENDPOINT:

      TO COMPARE THE EFFICACY OF TWO DOSES (25 MG AND 100 MG) OF RIFAXIMIN VAGINAL TABLETS VERSUS
      METROGEL VAGINAL IN SUBJECTS WITH BACTERIAL VAGINOSIS.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    According to the Recommendation of the Indipendent Data Monitoring Committee
  </why_stopped>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CLINICAL CURE OF BACTERIAL VAGINOSIS</measure>
    <time_frame>Day 22-30</time_frame>
    <description>RESOLUTION OF 3 OUT OF 4 AMSEL'S CRITERIA, I.E. NORMAL PHYSIOLOGICAL DISCHARGE, NEGATIVE &quot;WHIFF TEST&quot;, CLUE CELLS &gt;20%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BACTERIOLOGICAL CURE OF BACTERIAL VAGINOSIS</measure>
    <time_frame>Day 22-30</time_frame>
    <description>GRAM STAIN NUGENT SCORE &lt;4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>THERAPEUTIC CURE OF BACTERIAL VAGINOSIS</measure>
    <time_frame>Day 22-30</time_frame>
    <description>AMSEL'S CRITERIA AND GRAM STAIN NUGENT (RESOLUTION OF 3 OUT OF 4 AMSEL'S CRITERIA AND NUGENT SCORE &lt;4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAINTENANCE OF CLINICAL CURE OF BACTERIAL VAGINOSIS</measure>
    <time_frame>Day 61-70</time_frame>
    <description>AMSEL'S CRITERIA (RESOLUTION OF 3 OUT OF 4 AMSEL'S CRITERIA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAINTENANCE OF BACTERIOLOGICAL CURE OF BACTERIAL VAGINOSIS</measure>
    <time_frame>Day 61-70</time_frame>
    <description>NUGENT SCORE &lt;4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAINTENANCE OF THERAPEUTIC CURE OF BACTERIAL VAGINOSIS</measure>
    <time_frame>60-69 DAYS AFTER THE FIRST DAY OF TREATMENT</time_frame>
    <description>AMSEL'S CRITERIA AND NUGENT SCORE (MAINTENANCE OF RESOLUTION OF 3 OUT OF 4 AMSEL'S CRITERIA AND NUGENT SCORE &lt;4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NUMBER, INTENSITY AND TYPE OF ADVERSE EVENTS</measure>
    <time_frame>Up to Day 70</time_frame>
    <description>The incidence of adverse events to be summarized by body system and MedDRA preferred term.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LOCAL OBJECTIVE TOLERABILITY</measure>
    <time_frame>Day 22-30</time_frame>
    <description>Vaginal mucosa status in terms of erythema (score 0 to 3), edema (score 0 to 3), pethechial hemorrhages (absence/presence), ulcers (absence/presence)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LOCAL SUBJECTIVE TOLERABILITY</measure>
    <time_frame>Day 1 to Day 5</time_frame>
    <description>Grade (from 0 to 4) of vaginal itching, pain and burning</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">392</enrollment>
  <condition>BACTERIAL VAGINOSIS</condition>
  <arm_group>
    <arm_group_label>RIFAXIMIN VAGINAL TABLET 25 MG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RIFAXIMIN VAGINAL TABLET 25 MG ADMINISTERED ONCE A DAY FOR 5 DAYS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RIFAXIMIN VAGINAL TABLET 100 MG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RIFAXIMIN VAGINAL TABLET 100 MG ADMINISTERED ONCE A DAY FOR 5 DAYS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO VAGINAL TABLET</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PLACEBO VAGINAL TABLET ADMINISTERED ONCE A DAY FOR 5 DAYS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>METROGEL VAGINAL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>METROGEL VAGINAL ADMINISTERED ONCE A DAY FOR 5 DAYS</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RIFAXIMIN VAGINAL TABLET 25 MG</intervention_name>
    <description>RIFAXIMIN VAGINAL TABLET 25 MG O.D./5 DAYS INTRAVAGINALLY</description>
    <arm_group_label>RIFAXIMIN VAGINAL TABLET 25 MG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RIFAXIMIN VAGINAL TABLET 100 MG</intervention_name>
    <description>RIFAXIMIN VAGINAL TABLET 100 MG O.D./5 DAYS INTRAVAGINALLY</description>
    <arm_group_label>RIFAXIMIN VAGINAL TABLET 100 MG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLACEBO VAGINAL TABLET</intervention_name>
    <description>PLACEBO VAGINAL TABLET O.D./5 DAYS INTRAVAGINALLY</description>
    <arm_group_label>PLACEBO VAGINAL TABLET</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>METROGEL VAGINAL</intervention_name>
    <description>METROGEL VAGINAL O.D./5 DAYS INTRAVAGINALLY</description>
    <arm_group_label>METROGEL VAGINAL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of bacterial vaginosis with Amsel's criteria (4 out of 4 fulfilled
             criteria):

               -  Off white (milky or gray), thin, homogeneous, adherent vaginal discharge

               -  pH &gt;4.5

               -  Positive &quot;whiff test&quot;

               -  Presence of clue cells ≥20%

          -  Bacteriological diagnosis of bacterial vaginosis with Gram stain Nugent score ≥ 4
             (patients may be enrolled/randomized without this result)

          -  Post-menarchal, pre-menopausal female patient

          -  Non-pregnant (negative urine pregnancy test at Entry Visit/V1) nor breast-feeding
             patient

          -  Patient aged between 18 50 years, inclusively

          -  Patient who is willing to be asked questions about personal medical health and sexual
             history

          -  Patient capable of and willing to conform to the study protocol

          -  Patient who have been thoroughly informed of the aim of the study and the study
             procedures and who provided signed and dated written informed consent form

          -  Patient who agrees to abstain from intercourse during the 5 day treatment period

          -  Patient who agrees also to abstain from intercourse 3 days before the scheduled visits
             of follow-up

          -  Patient who agrees to abstain from the use of any other intravaginal product (i.e.,
             douching, feminine deodorants sprays, tampons, spermicides, gels, foams, vaginal birth
             control ring and diaphragms) during the entire study period

          -  Patient who agrees to use an adequate method of birth control for the duration of the
             study to avoid pregnancy. Acceptable methods include a history of bilateral tubal
             ligation, male partner with a vasectomy, a hormonal contraceptive [oral, patch,
             injectable or implantable (excluding intrauterine implantable devices [IUD],
             intrauterine system [IUS] and vaginal rings), or abstinence

          -  Patient who agrees to abstain from alcohol ingestion during the 5-day treatment period
             and for 1 day afterward

        Exclusion Criteria:

          -  Virginity

          -  Patient with other infectious causes of vulvovaginitis (e.g., candidiasis, Trichomonas
             vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, active Herpes simplex
             lesions, or Human Papilloma Virus lesions); patients may be enrolled/randomized
             without these results)

          -  Other vulvovaginal or cervical conditions, abnormalities or disorders confounding the
             interpretation of clinical response (including total hysterectomy)

          -  Symptoms suggestive of pelvic inflammatory disease

          -  Patient with intra uterine device (IUD), intrauterine system (IUS), or vaginal ring as
             contraceptive method

          -  Patient with severe hepatic insufficiency (Child C)

          -  Patient with severe cardiac insufficiency (NYHA - New York Heart Association classes 3
             - 4)

          -  Patient who will be being evaluated, including colposcopy and cervical biopsies, or
             being treated during the study period, for abnormal Pap test or cervical carcinoma. To
             note that if the Pap test will be performed at baseline, the result will be known
             after the randomization visit: patients may be enrolled without this result

          -  Any condition or circumstance that would prevent completion of the study or interfere
             with analysis of study results, including a history of drug or alcohol abuse, mental
             illness or non-compliance with treatments or visits, immunological (including HIV
             infection), hematological or neoplastic disease (including all cervical neoplastic
             diseases)

          -  Cervical cryotherapy, loop electrosurgical excision (LEEP), cervical laser, or any
             other ablative or excisional cervical procedures within the last 3 months

          -  Vaginal laser within the last 3 months

          -  Patient with clinically relevant pathological laboratory values

          -  Known hypersensitivity to rifaximin

          -  Known hypersensitivity to excipients present in rifaximin, placebo or metronidazole
             formulations

          -  Known hypersensitivity to metronidazole, either orally or topically administered, or
             any forms of parabens

          -  Concurrent anticoagulant therapy with coumadin or warfarin

          -  Menstruating or anticipated menstruation/withdrawal bleed at Entry Visit/V1 and during
             the drug administration

          -  Patient who received antifungal or antimicrobial therapy (systemic or intravaginal)
             within 14 days of randomization

          -  Patient who have participated in another clinical trial or have taken an
             investigational drug within the last 4 weeks prior screening

          -  Patient who has taken disulfuram within the last 14 days

          -  Withdrawal of informed consent

          -  Patient previously randomized in this study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raffaella Tacchi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alfasigma S.p.A.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>College of Medicine Drexel University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>191012-1192</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2015</study_first_submitted>
  <study_first_submitted_qc>February 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2015</study_first_posted>
  <last_update_submitted>October 7, 2016</last_update_submitted>
  <last_update_submitted_qc>October 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginal Diseases</mesh_term>
    <mesh_term>Vaginosis, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
    <mesh_term>Rifamycins</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

